Department of Neurosciences, Psychology, Pharmacology, and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
Stroke Unit, Careggi University Hospital, Firenze, Italy.
Neurol Sci. 2022 Apr;43(4):2433-2439. doi: 10.1007/s10072-021-05615-2. Epub 2021 Oct 5.
TIA and stroke, both ischemic and hemorrhagic, may complicate Fabry disease at young-adult age and be the first manifestation that comes to the clinician's attention. No definite indications have yet been elaborated to guide neurologists in Fabry disease diagnostics. In current practice, it is usually sought in case of cryptogenic strokes (while Fabry-related strokes can also occur by classical pathogenic mechanisms) or through screening programs in young cerebrovascular populations. Data on recurrence and secondary prevention of Fabry's stroke are scanty.
The study had a prospective observational design involving 33 Italian neurological Stroke Units. Considering the incidence of TIA/stroke in the European population aged < 60 years and the frequency of Fabry disease in this category (as foreseen by a pilot study held at the Careggi University-Hospital, Florence), we planned to screen for Fabry disease a total of 1740 < 60-year-old individuals hospitalized for TIA, ischemic, or hemorrhagic stroke. We investigated TIA and stroke pathogenesis through internationally validated scales and we gathered information on possible early signs of Fabry disease among all cerebrovascular patients. Every patient was tested for Fabry disease through dried blood spot analysis. Patients who received Fabry disease diagnosis underwent a 12-month follow-up to monitor stroke recurrence and multi-system progression after the cerebrovascular event.
The potential implications of this study are as follows: (i) to add information about the yield of systematic screening for Fabry disease in a prospective large cohort of acute cerebrovascular patients; (ii) to deepen knowledge of clinical, pathophysiological, and prognostic characteristics of Fabry-related stroke.
TIA 和缺血性或出血性中风都可能在青壮年时期使法布瑞氏病复杂化,且可能是临床医生首先注意到的表现。目前尚无明确的指标来指导神经科医生进行法布瑞氏病的诊断。在目前的实践中,通常在隐源性中风(而法布瑞相关的中风也可能通过经典的发病机制发生)或在年轻的脑血管人群中通过筛查计划来寻找该病。关于法布瑞氏中风的复发和二级预防的数据很少。
本研究采用前瞻性观察设计,涉及 33 家意大利神经科卒中单元。考虑到欧洲<60 岁人群 TIA/中风的发生率以及该年龄段法布瑞氏病的发病率(根据佛罗伦萨 Careggi 大学医院进行的一项试点研究预测),我们计划对 1740 名因 TIA、缺血性或出血性中风住院的<60 岁患者进行法布瑞氏病筛查。我们通过国际公认的量表研究 TIA 和中风的发病机制,并在所有脑血管病患者中收集可能的法布瑞氏病早期征象的信息。对每位患者通过干血斑分析进行法布瑞氏病检测。对确诊为法布瑞氏病的患者进行 12 个月的随访,以监测脑血管事件后的中风复发和多系统进展情况。
本研究的潜在意义如下:(i)在急性脑血管病患者的前瞻性大队列中,系统筛查法布瑞氏病的结果提供更多信息;(ii)深入了解法布瑞氏相关中风的临床、病理生理和预后特征。